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(project Q). Study A is complemented by 4 interrelated
add-on projects focusing on attachment style (study B1), on 
cost-effectiveness (study B2), on variation in the serotonin 
transporter gene in SP (study C1) and on structural and func-
tional deviations of the hippocampus and amygdala (study 
C2). Thus, the Social Phobia Psychotherapy Research Net-
work program enables a highly interdisciplinary research 
into SP. The unique sample size achieved by the multicenter 
approach allows for studies of subgroups (e.g. comorbid dis-
orders, isolated vs. generalized SP), of responders and non-
responders of each treatment approach, for generalization 
of results and for a sufficient power to detect differences be-
tween treatments. Psychological and biological parameters 
will be related to treatment outcome, and variables for dif-
ferential treatment indication will be gained. Thus, the re-
sults provided by the network may have an important im-
pact on the treatment of SP and on the development of 
treatment guidelines for SP.  Copyright © 2008 S. Karger AG, Basel 
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 Abstract 
 This paper presents the Social Phobia Psychotherapy Re-
search Network. The research program encompasses a coor-
dinated group of studies adopting a standard protocol and 
an agreed-on set of standardized measures for the assess-
ment and treatment of social phobia (SP). In the central proj-
ect (study A), a multicenter randomized controlled trial, re-
fined models of manualized cognitive-behavioral therapy 
and manualized short-term psychodynamic psychotherapy 
are compared in the treatment of SP. A sample of 512 outpa-
tients will be randomized to either cognitive-behavioral 
therapy, short-term psychodynamic psychotherapy or wait-
ing list. Assessments will be made at baseline, at the end of 
treatment and 6 and 12 months after the end of treatment. 
For quality assurance and treatment integrity, a specific proj-
ect using highly elaborated measures has been established 
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 Introduction 
 In order to fill specific lacks in international psycho-
therapy research, the Ministry of Education and Research 
of Germany has set up a research program 1 . A committee 
of international experts in psychotherapy research rec-
ommended the Social Phobia Psychotherapy Research 
Network (SOPHO-NET) for funding 2 . This article intro-
duces the SOPHO-NET research program 3 .
 Social phobia (SP) is a frequent, chronic and severely 
impairing mental disorder  [1–4] . Although the available 
treatments proved to be beneficial for SP  [5–11] , the rates 
of treatment responders are not yet satisfactory  [5, 10, 11] . 
Furthermore, the neurobiological basis of SP has received 
only limited investigation  [12–14] . Thus, further studies 
addressing both the efficacy of psychotherapy in SP and 
its neurobiology are required.
 The research program of the SOPHO-NET 4 encom-
passes a coordinated group of studies adopting a stan-
dard protocol and an agreed-on set of standardized mea-
sures for the assessment and treatment of SP. In addition 
to the scientific projects, a specific unit (Q) has been es-
tablished for project management and quality assurance 
(principal investigator: Dr. Leibing, Göttingen). Q coop-
erates closely with institutions specialized for data man-
agement and project management. The network includes 
highly interdisciplinary and interrelated research proj-
ects. For the first time  [15] , manualized cognitive-behav-
ioral therapy (CBT) and manualized short-term psycho-
dynamic psychotherapy (STPP) are compared in a large-
scale multicenter study of SP (study A). By highly 
elaborated measures, investigator allegiance effects are 
controlled for (see below). The unique sample size (n = 
512) achieved by the multicenter approach will allow for 
subgroup analyses (e.g. comorbid disorders), for the iden-
tification of responders and nonresponders of each treat-
ment approach, for a sufficient power to detect differenc-
es between treatments and for generalization of results. 
Psychological, genetic, neural and health economic pa-
rameters will be related to treatment outcome, and vari-
ables for differential treatment indication will be gained. 
Thus, the results provided by the network may have an 
important impact on the treatment of SP and on the de-
velopment of treatment guidelines.
 Methods and Description of the Network Projects 
 In the following, the research projects presently carried out by 
the SOPHO-NET will be described. The focus will be on the ran-
domized controlled treatment study (study A).
 Design of the Multicenter Treatment Study A 5 
For future studies of SP, experts in the field recommended a 
multicenter approach  [16] . Study A is a randomized controlled 
multicenter study comparing STPP and CBT under equal condi-
tions in the treatment of SP (principal investigator of study A: Dr. 
Leichsenring, Giessen). As an additional control condition, a 
waiting list group is included. Five research sites participate in the 
trial (Universities of Bochum/Dortmund, Dresden, Göttingen, 
Jena and Mainz). In order to ensure a sufficient power, a total of 
512 patients will be randomized to 1 of the 3 conditions ( fig. 1 ).
 Patient Inclusion and Exclusion Criteria 
 The following inclusion criteria are applied: diagnosis of SP 
(SCID I) and Liebowitz Social Anxiety Scale score  1 30  [17] , as well 
as age: 18–59 and 60–70 years (allowing to test for effects of age). 
SP must be the primary diagnosis, i.e. the severest disorder ac-
cording to ADIS-IV rating  [18, 19] . By including comorbid disor-
ders – provided that SP is the severest disorder – a clinically rep-
resentative sample will be gained, allowing to analyze the impact 
of comorbid disorders on the outcome. A rate of 60% of women 
will be included, reflecting the high prevalence of SP in women 
 [2] . The following conditions are excluded from the trial: psy-
chotic disorders, prominent risk of self-harm, acute substance-
related disorders, personality disorders except for avoidant, ob-
sessive-compulsive or dependent personality disorder (as assessed 
by SCID-II); organic mental disorder; severe medical conditions; 
concurrent psychotherapeutic or psychopharmacological treat-
ment.
 Assessment 
 Assessments are carried out at baseline, and in weeks 8, 15 and 
25 (after treatment). This procedure is analogous to Davidson et 
al.  [11] . The primary endpoints are in week 25 (after treatment) 
and 6 and 12 months after the end of treatment. Assessments in 
weeks 8 and 15 ensure intent-to-treat analyses. As studies of long-
term effects in SP are scant  [20] , follow-up studies will be carried 
out not only 6 months but also 12 months after termination of 
treatment (consistent with EMEA guidelines 6 ). The assessment 
instruments and their purposes are described in  table 1 . For qual-
ity assurance, all diagnostic sessions will be videotaped. The in-
terrater reliability for all observer-rated instruments will be care-
fully controlled. For the self-report instruments used in the study, 
sufficient psychometric properties have been demonstrated (see 
references in  table 1 ).
 1  http://www.bmbf.de/press/1336.php. 
 2  BMBF 01GV0607. 
 3  www.sopho-net.de
 4  The SOPHO-NET is supported by the following international experts: 
Dr. Barber and Dr. Crits-Christoph (University of Pennsylvania), Dr. Bö-
gels and Dr. Wijts (University of Maastricht), Dr. Clark (King’s College 
London), Dr. Gabbard (Baylor College of Medicine Houston), Dr. Kendall 
(University of Philadelphia), Dr. Pilkonis (University of Pittsburgh, Penn-
sylvania). 
 5   www.controlled-trials.com/ISRCTN53517394. 
 6  www.emea.eu.int/pdfs/human /ewp/363503en.pdf. 
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 Sample Sizes and Power Calculations for Study A 
 In order to detect even a small difference between CBT and 
STPP, which corresponds to a difference in response rates of 15% 
(h = 0.30)  [21] , 217 patients are required in each treatment group 
to achieve a statistical power of 0.90 at   = 0.05 using a 2-tailed 
test. The dropout rates of psychotherapy studies of SP range from 
9.2%  [22] to 28%  [11] , with a mean dropout rate of 15%. At a drop-
out rate of 15%, a total sample of 512 patients is required to ensure 
a high statistical power.
 Patient Recruitment 
 All of the participating centers run well-established outpatient 
clinics. Patients will be recruited by these institutions. Informa-
tion about SP and the SOPHO-NET research projects will be pub-
lished by the mass media in order to recruit a sufficient number 
of patients.
 Treatments Applied in Study A 
 CBT and STPP are the methods most frequently applied in 
clinical practice to treat anxiety disorders  [23] . As the response 
rates of the available treatments are not yet sufficient, further re-
search is required. Experts in the field suggest that the response 
rates may be improved by longer and more intensive treatment  [5] . 
Thus, in the present study up to 30 sessions of CBT or STPP are 
carried out. The CBT applied in the present study is based on 
Clark’s Cognitive Therapy  [24] , which was shown to be effica-
cious in several trials  [8, 10, 25] . This approach differs in some 
essential components from the program designed by Heimberg et 
al.  [26] , which is currently one of the best supported psychothera-
peutic treatments for SP. Clark and Wells’  [24] approach has a 
wider range of therapeutic procedures, all of which explicitly fo-
cus on reversing the maintaining processes specified in their 
model  [27] . This approach includes the following steps: (1) an in-
dividual version of the Clark and Wells model is derived along 
with the patient. It serves as a point of reference during the treat-
ment; (2) key safety behaviors are identified and their dysfunc-
tional effects are demonstrated with an experiential exercise in 
which patients role-play difficult social situations while focusing 
attention on themselves and using their safety behaviors and then 
focusing attention externally and attempt to drop their safety be-
haviors; (3) patients are trained to focus their attention externally, 
to reduce their dysfunctional self-monitoring and to obtain more 
accurate information on how they are responded to by others; (4) 
videofeedback is applied to demonstrate the discrepancy between 
their distorted self-images and their actual social performance; 
(5) extensive use of behavioral experiments is made in which pa-
tients specify their feared outcomes for various social situations 
and then test out whether they occurred during planned expo-
sure, and (6) problematic anticipatory or postevent processing is 
identified and modified, and dysfunctional assumptions are 
Allocation
Analysis
Follow-up
6 months
12 months
Assessed for eligibility
(planned) (n = 1,253)
Enrollment
Randomized
(n = 512)
incl. waiting list
Allocated to intervention STPP
(planned) (n = 256)
Allocated to intervention CBT
(planned) (n = 256)
Analyzed (n = 217)
(planned)
Analyzed (n = 217)
(planned)
Lost to follow-up or discontinued
intervention
(planned, 15%) (n = 39)
Lost to follow-up or discontinued
intervention
(planned, 15%) (n = 39)
 Fig. 1. Consort flowchart of the SOPHO-
NET treatment study A. 
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modified by behavioral experiments and cognitive restructuring. 
With regard to psychodynamic therapy, 2 studies demonstrated 
the efficacy of STPP in the treatment of SP  [6, 9] . However, in 
these studies the sample size was small or no treatment manual 
was used for STPP. In the present study, a treatment manual for 
STPP that is based on Luborsky’s Supportive-Expressive Therapy 
(SET)  [28] will be used. SET is among the empirically best sup-
ported manualized models of STPP  [29] . SET focuses on the ‘Core 
Conflictual Relationship Theme’ (CCRT)  [28, 30] . A CCRT con-
sists of 3 components: a wish (W), a response from the others (RO) 
and a response from the self (RS). In this scheme, RS represents 
the patient’s symptoms, e.g. SP. For a patient with SP, the CCRT 
could be, for example: ‘I wish to be approved of by others (W). 
However, the others will humiliate me (RO). I feel ashamed and 
get afraid of meeting other people, so I have decided to avoid ex-
posing myself ’ (RS, symptoms of SP). SET uses both supportive 
and expressive interventions. In SET the establishment of a help-
ing alliance is a central aspect of supportive interventions  [28] . 
Expressive (i.e. interpretive) interventions enhance the patient’s 
cognitive and emotional understanding of his or her present 
symptoms and of the underlying CCRT  [28] . In order to tailor SET 
specifically to the treatment of SP, the psychodynamic research 
group of the SOPHO-NET integrated specific principles for inter-
ventions derived from the psychodynamic models of SP  [31, 32] 
into SET  [33] . This SP-specific manual will be used in the present 
study. The SP-specific intervention principles include the follow-
ing: (a) informing the patient about the disorder at the beginning 
of treatment; (b) establishing a secure positive therapeutic alli-
ance to modify insecure attachments; (c) focusing on the affect of 
shame and point out its central role in SP; (d) encouraging the 
patient to actively confront rather than avoid the anxiety-produc-
ing situation; (e) supporting the patient in establishing a self-af-
firming inner dialogue; (f) exploring and discussing the use of 
psychotropic substances and medication used by many patients 
with SP to reduce anxiety, and (g) helping the patient improve 
social skills. Further interventions specific to the treatment of SP 
including, for example, the handling of counter-transference 
problems are described in the treatment manual  [33] . Whereas the 
Clark and Wells approach has already been used in controlled 
studies and the CBT therapists of our study are already familiar 
Table 1. Assessment instruments and time of assessment of study A and study B2
Purpose Domain Instrument Perspective Screening Before 
treatment
8 and 
15 weeks
After 
treatment
6-/12-month
follow-up
Screening SCID I, II Independent rater x
ADIS-IV rating Independent rater x x x x
LSAS Independent rater x
Outcome Social phobia 
 diagnosis 
SCID I Independent rater x x x x
Social phobia 
 symptoms
LSAS primary
outcome measure
Independent rater x x x x
Social phobia 
 symptoms
SPAI Patient x x x
Interpersonal 
 functioning
IIP Patient x x x
Self-concept FSKN Patient x x x
Depression BDI Patient x x x
Shame TOSCA Patient x x x
Costs CSSRI Patient x x x
Utilities/quality
of life
EQ-5D, 
SF-12/SF-6 D
Patient x x x
Process Helping alliance HAQ Patient x x
Treatment integrity PACS-SE Patient x
Conflicts CCRT Independent rater sessions 3 and 5 vs. 17 and 18
Adherence and 
 competence
PACS-SE,
CTACS
Independent rater randomly selected sessions
ADIS-IV = Anxiety Disorders Interview Schedule Adult Version (rating scale for severity of symptoms) [18, 19]; BDI = Beck 
 Depression Inventory [41]; CCRT = Core Conflictual Relationship Theme Method [28, 30]; CSSRI = Client Sociodemographic and 
Service Receipt Inventory [42, 43]; CTACS = Cognitive Therapy Adherence and Competence Scale [35]; EQ-5D = EuroQol Question-
naire [44–46]; FSKN = Frankfurter Selbstkonzept-Skalen (Frankfurt Self-Concept Scales) [47]; HAQ = Helping Alliance Question-
naire [48]; IIP = Inventory of Interpersonal Problems [49]; LSAS = Liebowitz Social Anxiety Scale [50]; PACS-SE = Penn Adherence 
and Competence Scale for SET [28, 36]; SCID I = Structured Clinical Interview for DSM-IV Axis I Disorders [51]; SCID II = Structured 
Clinical Interview for DSM-IV Axis II Disorders [51]; SF-12/SF-6 D = Fragebogen zum Gesundheitszustand (Quality of Life Question-
naire) [52, 53]; SPAI = Social Phobia and Anxiety Inventory [54, 55]; TOSCA = Test of Self-Conscious Affects [56, 57].
 Social Phobia Psychotherapy Research 
Network 
Psychother Psychosom 2009;78:35–41 39
with it, the STPP approach is based on a new manual. Thus, CBT 
is expected to be superior in the first 50% of the treated patients. 
In the second half of the treated patients, these differences are 
likely to decrease.
 Treatment Implementation and Treatment Integrity (Q) 
 As mentioned above, a specific unit (Q) for project manage-
ment and quality assurance has been developed. Within Q, a spe-
cial subunit has been established to ensure adequate and compa-
rable treatment implementation in all trial sites as well as reliabil-
ity of diagnostic assessments. Representatives of both CBT (Dr. 
Stangier) and STPP (Dr. Beutel) are responsible for adequate im-
plementation of each approach. By this procedure, investigator 
allegiance effects are balanced between the 2 rival approaches and 
controlled for. A total of at least 20 therapists per treatment con-
dition are included. In order to be accepted into the trial, thera-
pists must have an advanced or completed clinical training of 
CBT or STPP, respectively. In both treatment conditions thera-
pists receive equivalent manualized training and supervision 
 [34] . Before treating study patients, therapist’s competence is en-
hanced in a 20-hour training program. During the trial, thera-
pists receive group supervision by highly experienced and spe-
cifically trained local supervisors. Supervision is carried out ev-
ery 2 weeks during the first 6 months of the treatment phase and 
monthly during the remaining 12 months. Adherence and com-
petence for CBT is assessed by use of the Cognitive Therapy Ad-
herence and Competence Scale (CTACS)  [35] , for STPP by use of 
the Penn Adherence and Competence Scale for Supportive-Ex-
pressive Therapy (PACS-SE)  [28, 36] . CTACS and PACS-SE are 
applied to videotaped therapy sessions. For that purpose, inde-
pendent raters receive 60 h of training  [37] following the training 
procedures by Barber and Crits-Christoph  [38] for STPP and by 
Hill et al.  [37] for CBT. Randomly selected videotapes will be used 
for interrater reliability assessment. To be included in the study, 
therapists have to demonstrate a sufficient level of competence in 
the treatment of at least 2 pilot cases before conducting actual 
trial therapies. Recommended by Dr. Barber, this therapist pre-
requisite relies on a cutoff value of  6 4 in CTACS and PACS-SE, 
respectively, as a criterion for acceptable competence. During the 
trial, therapists are supported by continuous feedback given by 
the local trial site supervisors to prevent ‘drifting’. Additionally, 
as a backup, the subunit responsible for treatment implementa-
tion will evaluate randomly selected videotapes of therapy ses-
sions. Should the therapeutical quality fall below the ‘red line’, 
therapists will be given feedback. Those who fail to meet manual-
ized standards will receive additional supervision. Should the 
therapists continue to provide less than adequate therapeutical 
performance, they will be withdrawn from the study. For the sta-
tistical evaluation of treatment integrity, PACS-SE and CTACS 
will be applied by blind raters to randomly drawn videotaped ses-
sions. The 2 treatments are expected to differ significantly with 
regard to manualized treatment-specific interventions  [39] .
 Add-On Projects of the Network 
 Study A is complemented by 4 add-on projects highly relevant 
to SP. For reasons of space limitations, the add-on projects will be 
described in more detail elsewhere. Project B1 examines the as-
sociation between attachment style and treatment outcome (prin-
cipal investigator: Dr. Strauss, Jena). Patients revealing a secure 
organized attachment are expected to achieve a better outcome 
than patients with insecure features and/or disorganized states of 
mind. Furthermore, self-reported attachment is likely to change 
after successful therapy, indicating increased security. In project 
B2, an economic evaluation of STPP and CBT will be conducted 
alongside the multicenter treatment study A. The direct and in-
direct costs, utilities, quality-adjusted life years and incremental 
cost-effectiveness ratios of the treatment strategies (STPP, CBT, 
waiting list) will be measured and compared (principal investiga-
tor: Dr. König, Leipzig). Project C1 explores the impact of genetic 
variation in the serotonin transporter gene on the severity of SP 
and on the outcome of psychotherapy (principal investigator: Dr. 
Vormfelde, Göttingen). The short allele and the S 10 allele are ex-
pected to predispose to severer symptoms of SP. The long allele 
and specifically the L 12 haplotype are predicted to be associated 
with a more favorable treatment outcome. In project C2, struc-
tural and functional abnormalities of amygdala and hippocam-
pus in patients with SP are examined by neuroimaging including 
their possible therapy-induced changes after CBT or STPP, re-
spectively (principal investigator: Dr. Irle, Göttingen). In study 
C2, both healthy control subjects and panic disorder patients 
serve as controls.
 Discussion 
 The SOPHO-NET research plan presented here imple-
ments a number of methodological refinements that have 
previously been suggested. Among these methodological 
and substantial perspectives are the following: (a) estab-
lishing a specific unit for quality assurance, and for pro-
gram and data management; (b) comparison of the psy-
chotherapeutic treatments that are most common and 
relevant for clinical practice; (c) use of refined treatment 
models to improve responder rates; (d) highly elaborated 
measures to ensure treatment integrity; (e) methods 
against bias, in particular control for investigator alle-
giance effects (e.g. by co-investigatorship of experts in 
CBT and STPP, assurance of adherence and competence); 
(f) multicenter approach allowing for tests of generaliz-
ability and subgroup analyses (e.g. patients benefiting 
most and least from STPP or CBT; study of nonre-
sponders); (g) inclusion of comorbid disorders to ensure 
clinically representative samples and to study the impact 
of comorbid disorders on outcome; (h) study of gender 
and developmental aspects (focus on women and elderly); 
(i) study of attachment styles as predictors of outcome; (j) 
inclusion of neurobiological research, and (k) inclusion 
of cost-effectiveness analysis. In detail, the following hy-
potheses will be tested in the SOPHO-NET projects: with 
regard to the treatment study A, the insufficient response 
rates reported in the presently available studies of SP are 
expected to be improved by a longer and more intensive 
treatment of up to 30 sessions. Differential effects are hy-
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